- Home
- UROY vs CBLL Comparison
UROY vs CBLL Comparison
Compare UROY & CBLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UROY
- CBLL
- Stock Information
- Founded
- UROY 2017
- CBLL 2014
- Country
- UROY Canada
- CBLL United States
- Employees
- UROY N/A
- CBLL N/A
- Industry
- UROY
- CBLL
- Sector
- UROY
- CBLL
- Exchange
- UROY Nasdaq
- CBLL Nasdaq
- Market Cap
- UROY 438.3M
- CBLL 433.7M
- IPO Year
- UROY N/A
- CBLL 2024
- Fundamental
- Price
- UROY $4.03
- CBLL $12.95
- Analyst Decision
- UROY Strong Buy
- CBLL Strong Buy
- Analyst Count
- UROY 1
- CBLL 7
- Target Price
- UROY $4.50
- CBLL $30.67
- AVG Volume (30 Days)
- UROY 5.8M
- CBLL 258.5K
- Earning Date
- UROY 12-11-2025
- CBLL 11-04-2025
- Dividend Yield
- UROY N/A
- CBLL N/A
- EPS Growth
- UROY N/A
- CBLL N/A
- EPS
- UROY N/A
- CBLL N/A
- Revenue
- UROY $35,266,447.00
- CBLL $77,419,000.00
- Revenue This Year
- UROY $195.97
- CBLL $35.45
- Revenue Next Year
- UROY N/A
- CBLL $28.18
- P/E Ratio
- UROY N/A
- CBLL N/A
- Revenue Growth
- UROY 14.29
- CBLL 42.16
- 52 Week Low
- UROY $1.43
- CBLL $10.01
- 52 Week High
- UROY $5.37
- CBLL $32.75
- Technical
- Relative Strength Index (RSI)
- UROY 50.35
- CBLL 54.76
- Support Level
- UROY $3.69
- CBLL $12.54
- Resistance Level
- UROY $4.20
- CBLL $13.86
- Average True Range (ATR)
- UROY 0.35
- CBLL 0.64
- MACD
- UROY -0.07
- CBLL 0.07
- Stochastic Oscillator
- UROY 19.94
- CBLL 60.26
About UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is acquiring and assembling a portfolio of royalties, investing in companies with exposure to uranium and physical uranium. The Company also engages in the purchase and sale of physical uranium.
About CBLL CeriBell Inc.
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.